Show simple item record

dc.contributor.authorWilliams, SG
dc.contributor.authorAw Yeang, HX
dc.contributor.authorMitchell, C
dc.contributor.authorCaramia, F
dc.contributor.authorByrne, DJ
dc.contributor.authorFox, SB
dc.contributor.authorHaupt, S
dc.contributor.authorSchittenhelm, RB
dc.contributor.authorNeeson, PJ
dc.contributor.authorHaupt, Y
dc.contributor.authorKeam, SP
dc.date.accessioned2020-11-17T04:14:39Z
dc.date.available2020-11-17T04:14:39Z
dc.date.issued2020-10-28
dc.identifierpii: 10.1186/s12894-020-00738-8
dc.identifier.citationWilliams, S. G., Aw Yeang, H. X., Mitchell, C., Caramia, F., Byrne, D. J., Fox, S. B., Haupt, S., Schittenhelm, R. B., Neeson, P. J., Haupt, Y. & Keam, S. P. (2020). Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC UROLOGY, 20 (1), https://doi.org/10.1186/s12894-020-00738-8.
dc.identifier.issn1471-2490
dc.identifier.urihttp://hdl.handle.net/11343/251746
dc.description.abstractBACKGROUND: Understanding the drivers of recurrence in aggressive prostate cancer requires detailed molecular and genomic understanding in order to aid therapeutic interventions. We provide here a case report of histological, transcriptional, proteomic, immunological, and genomic features in a longitudinal study of multiple biopsies from diagnosis, through treatment, and subsequent recurrence. CASE PRESENTATION: Here we present a case study of a male in 70 s with high-grade clinically-localised acinar adenocarcinoma treated with definitive hormone therapy and radiotherapy. The patient progressed rapidly with rising PSA and succumbed without metastasis 52 months after diagnosis. We identified the expression of canonical histological markers of neuroendocrine PC (NEPC) including synaptophysin, neuron-specific enolase and thyroid transcription factor 1, as well as intact AR expression, in the recurrent disease only. The resistant disease was also marked by an extremely low immune infiltrate, extensive genomic chromosomal aberrations, and overactivity in molecular hallmarks of NEPC disease including Aurora kinase and E2F, as well as novel alterations in the cMYB pathway. We also observed that responses to both primary treatments (high dose-rate brachytherapy and androgen deprivation therapies) were consistent with known optimal responses-ruling out treatment inefficacy as a factor in relapse. CONCLUSIONS: These data provide novel insights into a case of locally recurrent aggressive prostate cancer harbouring NEPC pathology, in the absence of detected metastasis.
dc.languageEnglish
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleImmune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report
dc.typeJournal Article
dc.identifier.doi10.1186/s12894-020-00738-8
melbourne.affiliation.departmentCentre for Cancer Research
melbourne.source.titleBMC Urology
melbourne.source.volume20
melbourne.source.issue1
melbourne.source.pages171-
dc.rights.licenseCC BY
melbourne.elementsid1470686
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592533
melbourne.contributor.authorHaupt, Susan
melbourne.contributor.authorNeeson, Paul
melbourne.contributor.authorHaupt, Ygal
melbourne.contributor.authorFox, Stephen
melbourne.contributor.authorWilliams, Scott
melbourne.contributor.authorAw Yeang, Han Xian
melbourne.contributor.authorKeam, Simon
dc.identifier.eissn1471-2490
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record